HomeCompareAVGR vs EQR

AVGR vs EQR: Dividend Comparison 2026

AVGR yields 421.94% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVGR wins by $180.8K in total portfolio value
10 years
AVGR
AVGR
● Live price
421.94%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$228.6K
Annual income
$477.83
Full AVGR calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — AVGR vs EQR

📍 AVGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVGREQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVGR + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVGR pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVGR
Annual income on $10K today (after 15% tax)
$35,864.98/yr
After 10yr DRIP, annual income (after tax)
$406.16/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $4,248.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVGR + EQR for your $10,000?

AVGR: 50%EQR: 50%
100% EQR50/50100% AVGR
Portfolio after 10yr
$138.2K
Annual income
$2,976.72/yr
Blended yield
2.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

AVGR
Analyst Ratings
4
Buy
3
Hold
Consensus: Buy
Altman Z
-48.2
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVGR buys
0
EQR buys
0
No recent congressional trades found for AVGR or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVGREQR
Forward yield421.94%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.8%
Portfolio after 10y$228.6K$47.8K
Annual income after 10y$477.83$5,475.61
Total dividends collected$131.1K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: AVGR vs EQR ($10,000, DRIP)

YearAVGR PortfolioAVGR Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$31,797$21,097.05$11,380$679.82+$20.4KAVGR
2$65,370$31,346.90$13,014$837.25+$52.4KAVGR
3$100,060$30,114.17$14,961$1,036.20+$85.1KAVGR
4$128,604$21,539.72$17,297$1,289.22+$111.3KAVGR
5$150,543$12,936.60$20,121$1,613.15+$130.4KAVGR
6$168,157$7,076.40$23,561$2,030.84+$144.6KAVGR
7$183,622$3,693.63$27,783$2,573.54+$155.8KAVGR
8$198,360$1,884.73$33,013$3,284.39+$165.3KAVGR
9$213,196$951.40$39,547$4,223.51+$173.6KAVGR
10$228,598$477.83$47,791$5,475.61+$180.8KAVGR

AVGR vs EQR: Complete Analysis 2026

AVGRStock

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.

Full AVGR Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this AVGR vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVGR vs SCHDAVGR vs JEPIAVGR vs OAVGR vs KOAVGR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.